COVID-19 Implications for Patients with CLL: Living Slideset

Download this living slideset from the live Webinar on the management of patients with CLL during the COVID-19 pandemic and check back often for updates as the situation evolves and more data are available.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.55 MB
Released: July 2, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Related Content

John Pagel, MD, PhD discusses incorporating telemedicine and other strategies into the care plan for patients with CLL during COVID-19

John Pagel Headshot John Pagel, MD, PhD Released: July 13, 2020

BTK inhibitor, acalabrutinib, shows promising early clinical data in the treatment of hyperinflammatory response in patients with severe COVID-19

Jeff P. Sharman, MD Released: June 16, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?